candesartan + placebo
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis
Trial Timeline
May 1, 2009 → Dec 1, 2014
NCT ID
NCT00699452About candesartan + placebo
candesartan + placebo is a phase 3 stage product being developed by AstraZeneca for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00699452. Target conditions include Aortic Valve Stenosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00699452 | Phase 3 | UNKNOWN |
| NCT00319202 | Approved | Terminated |
| NCT00328302 | Approved | UNKNOWN |
| NCT00634712 | Phase 3 | Completed |
| NCT00634309 | Phase 3 | Completed |
| NCT00634400 | Phase 3 | Completed |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 72 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 77 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 85 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 77 |
| Sugammadex | Merck | Approved | 85 |
| bisoprolol + placebo | Merck | Approved | 85 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 65 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 52 |
| fluvastatin | Novartis | Phase 2 | 52 |
| ACZ885 + Placebo | Novartis | Phase 2 | 52 |
| Evolocumab + Placebo | Amgen | Phase 1 | 32 |
| atorvastatin (Lipitor) | Pfizer | Approved | 84 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 32 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 51 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 51 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 74 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 74 |
| Desflurane | Baxter | Approved | 82 |